OP0190 META-ANALYSIS OF IMMUNOCHIP DATA OF FOUR AUTOIMMUNE DISEASES REVEALS NOVEL SINGLE-DISEASE AND CROSS-PHENOTYPE ASSOCIATIONS
Authors: Ana Márquez, Martin Kerick, Alexandra Zhernakova, Javier Gutierrez-Achury, Wei-Min Chen, Suna Onengut-Gumuscu, Isidoro González-Álvaro, Luis Rodriguez-Rodriguez, Miguel A González-Gay, Maureen Mayes, Soumya Raychaudhuri, Stephen S. Rich, Cisca Wijmenga, Javier Martin Ibanez
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> In recent years, research has consistently proven the occurrence of genetic overlap across autoimmune diseases, which supports the existence of common pathogenic mechanisms in autoimmunity. <h3>Objectives</h3> The objective of this study was to further investigate this shared genetic component. <h3>Methods</h3> We performed a cross-disease meta-analysis of Immunochip data from 37,159 patients diagnosed with a seropositive autoimmune disease (11,489 celiac disease (CeD), 15,523 rheumatoid arthritis (RA), 3,477 systemic sclerosis (SSc), and 6,670 type 1 diabetes (T1D)) and 22,308 healthy controls of European origin using the R package ASSET. <h3>Results</h3> We identified 38 risk variants shared by at least two of the conditions analyzed, five of which represent new pleiotropic loci in autoimmunity. We also identified six novel genome-wide associations for the diseases studied. Cell-specific functional annotations and biological pathway enrichment analyses suggested that pleiotropic variants may deregulate gene expression in different subsets of T cells, especially Th17 and regulatory T cells. Finally, drug repositioning analysis evidenced several drugs that could represent promising candidates for CeD, RA, SSc and T1D treatment. <h3>Conclusion</h3> We have been able to advance in the knowledge of the genetic overlap existing in autoimmunity, thus shedding light on common molecular mechanisms of disease and suggesting novel drug targets that could be explored for the treatment of the autoimmune diseases studied. <h3>References</h3> [1] Richard-Miceli C, Criswell LA. Emerging patterns of genetic overlap across autoimmune disorders. Genome Med. 2012;4(1):6. [2] Bhattacharjee S, Rajaraman P, Jacobs KB, et al. A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits. Am J Hum Genet. 2012;90(5):821-35 <h3>Disclosure of Interests</h3> Ana Márquez: None declared, Martin Kerick: None declared, Alexandra Zhernakova: None declared, Javier Gutierrez-Achury: None declared, Wei-Min Chen: None declared, Suna Onengut-Gumuscu: None declared, Isidoro González-Álvaro: None declared, Luis Rodriguez-Rodriguez: None declared, Miguel A González-Gay Grant/research support from: Prof. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker's bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Maureen Mayes Grant/research support from: Maureen Mayes is a clinical trial investigator for Boehringer-Ingelheim; Galapagos, Reata, Sanofi, Merck-Serono, Consultant for: Maureen Mayes is a member of scientific advisory boards for Galapagos NV (Pharma), Boehringer-Ingelheim, Mitsubishi-Tanabe, Astellas: Grant Review Board for Actelion., Speakers bureau: Maureen Mayes received personal fees for being a conference speaker on the use of autoantibodies in connective tissue diseases for Medtelligence, Soumya Raychaudhuri: None declared, Stephen S. Rich: None declared, Cisca Wijmenga: None declared, Javier Martin Ibanez: None declared